← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CALCIUM CHANNEL BLOCKERS › SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS › Dihydropyridine derivatives
manidipine
C08CA11
Forms & Strengths
- Tablets: 10 mg
- Tablets: 20 mg
Adult Dosing
- Hypertension: 10 to 20 mg orally once daily in the morning after breakfast
- Maximum recommended dose: 20 mg once daily
- Hepatic impairment (mild to moderate): Initiate with 10 mg daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Mechanism of Action
- Dihydropyridine calcium channel blocker
- Inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle
- Selectively exerts higher affinity for vascular smooth muscle than cardiac tissue, leading to peripheral vasodilation and reduced blood pressure
Contraindications
- Hypersensitivity to manidipine or other dihydropyridines
- Unstable angina pectoris
- Acute myocardial infarction (within the first month)
- Severe hepatic impairment
- Untreated heart failure
Adverse Reactions
- Common: Peripheral edema, headache, dizziness, flushing, palpitations
- Less common: Fatigue, asthenia, nausea, dyspepsia, somnolence
- Rare: Hypotension, tachycardia, elevated liver enzymes, skin rash
Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir): May increase plasma concentrations of manidipine
- CYP3A4 inducers (e.g., rifampicin, carbamazepine, St. John's wort): May decrease plasma concentrations of manidipine
- Antihypertensive agents, diuretics, and nitrates: May enhance the blood pressure-lowering effect
- Alcohol: May enhance hypotensive effects
Curated Content: Needs Vetting Before Put to Clinical Use